OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19
Bin Cao, Yeming Wang, Hongzhou Lu, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 3, pp. 230-241
Open Access | Times Cited: 59
Bin Cao, Yeming Wang, Hongzhou Lu, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 3, pp. 230-241
Open Access | Times Cited: 59
Showing 1-25 of 59 citing articles:
Long COVID science, research and policy
Ziyad Al‐Aly, Hannah Davis, Lisa McCorkell, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2148-2164
Open Access | Times Cited: 79
Ziyad Al‐Aly, Hannah Davis, Lisa McCorkell, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2148-2164
Open Access | Times Cited: 79
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Predicting the hub interactome of COVID-19 and oral squamous cell carcinoma: uncovering ALDH-mediated Wnt/β-catenin pathway activation via salivary inflammatory proteins
Pradeep Kumar Yadalam, Deepavalli Arumuganainar, Prabhu Manickam Natarajan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Pradeep Kumar Yadalam, Deepavalli Arumuganainar, Prabhu Manickam Natarajan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
Anne F. Luetkemeyer, Kara W. Chew, Stuart R. Lacey, et al.
Clinical Infectious Diseases (2025)
Open Access | Times Cited: 1
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Treating Acute Covid-19 — Final Chapters Still Unwritten
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 12
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 12
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database
Robert Morris, Rahinatu Ali, Feng Cheng
Current Drug Targets (2024) Vol. 25, Iss. 7, pp. 454-464
Closed Access | Times Cited: 8
Robert Morris, Rahinatu Ali, Feng Cheng
Current Drug Targets (2024) Vol. 25, Iss. 7, pp. 454-464
Closed Access | Times Cited: 8
Synthesis and biological evaluation of novel peptidomimetic inhibitors of the coronavirus 3C-like protease
Franck Amblard, Julia C. LeCher, Ramyani De, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116263-116263
Closed Access | Times Cited: 6
Franck Amblard, Julia C. LeCher, Ramyani De, et al.
European Journal of Medicinal Chemistry (2024) Vol. 268, pp. 116263-116263
Closed Access | Times Cited: 6
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Agnieszka Zagórska, Anna Czopek, Monika Fryc, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 797-797
Open Access | Times Cited: 6
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Hongzhou Lu, George Zhang, John Mao, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102582-102582
Open Access | Times Cited: 5
Hongzhou Lu, George Zhang, John Mao, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102582-102582
Open Access | Times Cited: 5
Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Haiyu Wang, Guangying Cui, Ming Cheng, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Jiangtao Bai, Tetsuya Asakawa, Wenfang Yuan, et al.
Virology Journal (2025) Vol. 22, Iss. 1
Open Access
Synthesis and biological investigation of peptidomimetic SARS‐CoV‐2 main protease inhibitors bearing quinoline‐based heterocycles at P3
Sara Rossi, Graziano Deidda, Lia Fiaschi, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Closed Access
Sara Rossi, Graziano Deidda, Lia Fiaschi, et al.
Archiv der Pharmazie (2025) Vol. 358, Iss. 1
Closed Access
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Tin Phan, Ruy M. Ribeiro, Gregory E. Edelstein, et al.
Journal of Virology (2025)
Open Access
Nucleoside reverse transcriptase inhibition enhances platelet production and megakaryocyte maturation in patients with COVID ‐19
Yubin Li, Juan Wang, Bingqian Huang, et al.
British Journal of Haematology (2025)
Closed Access
Yubin Li, Juan Wang, Bingqian Huang, et al.
British Journal of Haematology (2025)
Closed Access
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Identifying Exifone as a Dual-Target Agent Targeting Both SARS-CoV-2 3CL Protease and the ACE2/S-RBD Interaction Among Clinical Polyphenolic Compounds
Jiani Lu, Yan Tang, Hongtao Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2243-2243
Open Access
Jiani Lu, Yan Tang, Hongtao Li, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 5, pp. 2243-2243
Open Access
Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrier
Liwei Zhao, Chuang Li, Mengyu Wang, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Liwei Zhao, Chuang Li, Mengyu Wang, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir–ritonavir in adult patients with COVID-19: A randomized, open-label, multicenter trial
Xiaohui Zou, Kang Chang, Guohui Fan, et al.
Science Bulletin (2024) Vol. 69, Iss. 12, pp. 1954-1963
Open Access | Times Cited: 3
Xiaohui Zou, Kang Chang, Guohui Fan, et al.
Science Bulletin (2024) Vol. 69, Iss. 12, pp. 1954-1963
Open Access | Times Cited: 3
Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (Mpro)
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
Yue Yang, Yidan Luo, Chenbo Zhang, et al.
ACS Omega (2024) Vol. 9, Iss. 32, pp. 34196-34219
Open Access | Times Cited: 3
SARS-CoV-2 antivirals and post-COVID-19 condition
Ziyad Al‐Aly
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Ziyad Al‐Aly
The Lancet Infectious Diseases (2024)
Closed Access | Times Cited: 3
Potent new pill provides COVID relief for the masses
Saima Sidik
Nature (2024) Vol. 625, Iss. 7996, pp. 644-644
Closed Access | Times Cited: 2
Saima Sidik
Nature (2024) Vol. 625, Iss. 7996, pp. 644-644
Closed Access | Times Cited: 2
An update on Long COVID
Gary Grohmann, Robert Booy
Microbiology Australia (2024)
Open Access | Times Cited: 2
Gary Grohmann, Robert Booy
Microbiology Australia (2024)
Open Access | Times Cited: 2
Emergence of SARS and COVID-19 and preparedness for the next emerging disease X
Ben Hu, Hua Guo, Hao-Rui Si, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 1, pp. 1-18
Closed Access | Times Cited: 2
Ben Hu, Hua Guo, Hao-Rui Si, et al.
Frontiers of Medicine (2024) Vol. 18, Iss. 1, pp. 1-18
Closed Access | Times Cited: 2
3C-like proteases in SARS-CoV-2
Kenana Al Adem, Juliana C. Ferreira, Adrian J. Villanueva, et al.
Bioscience Reports (2024)
Open Access | Times Cited: 2
Kenana Al Adem, Juliana C. Ferreira, Adrian J. Villanueva, et al.
Bioscience Reports (2024)
Open Access | Times Cited: 2
